DiaMedica Appoints John Savage as Chief Financial Officer

DiaMedica (TSX VENTURE:DMA) today announced the appointment of Mr. John Savage
as the Company's Chief Financial Officer. Mr. Savage has more than 17 years of
experience working with publicly traded companies.


"We are delighted to welcome John to DiaMedica," said Rick Pauls, DiaMedica's
President and CEO. "John brings a combination of strong financial and corporate
experience with publicly traded companies to help advance DiaMedica's business
strategy." 


Prior to joining DiaMedica, Mr. Savage was Director of Corporate Accounting at
UnitedHealth Group, a diversified health care company, where he also was
involved in the Diabetes Prevention and Control Alliance (DPCA). Previously, Mr.
Savage was with Best Buy and Golf Galaxy (acquired by Dick's Sporting Goods),
where he held increasingly progressive responsibilities. Mr. Savage began his
career with Deloitte & Touche LLP. He graduated Summa Cum Laude from the
University of St. Thomas with a Bachelor of Arts degree in Business
Administration.


The Company issued Mr. Savage 200,000 stock options in accordance with the Stock
Option Plan at an exercise price of CAD $0.83 and a term of 10 years. The
options are subject to acceptance by the TSX Venture Exchange. 


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
President & CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024